malignant lymphoma
Conditions
Interventions
None listed
Sponsors
Department of Advanced Cell and Molecular Therapy Kyushu University Hospital
Laboratory of DNA Information Analysis, Human Genome Center, The Institute of Medical Science, The University of Tokyo Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo Department of Immunology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama Department of Cancer Therapy and Research, Graduate School of Medical Sciences, Kyushu University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Adult patients who receive lymphoma tissue biopsy as daily medical practice 2) Patients who understand well and can agree with this study plan by himself
Exclusion criteria
Exclusion criteria: 1) Patients diagnosed as double cancer 2) Patients whom researchers judged inappropriate as a subject
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The absolute number and ratio of IFNg-producing CD8+ TILs after treatment by anthracyclin agents or other anticancer drugs. | — |
Secondary
| Measure | Time frame |
|---|---|
| The ratio and absolute number of CD8+ TILs expressing PD-1 or CD137, the ratio and count of Treg to CD4+T cells. Clinical findings (age, sex, prognosis), Blood count and biochemistry analysis. TCR clonality of above CD8+ TILs and antitumor effects of genetically modified T cells to express engineered TCR. Tumor-specific antigens obtained by exome sequencing analysis data. | — |
Countries
Japan
Contacts
Public ContactMutsunori Murahashi
Kyushu University Hospital Department of Advanced Cell and Molecular Therapy
Outcome results
None listed